Switch theme
Sign up to access all valuation multiples
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
2010
216
LTM Revenue $76.8M
LTM EBITDA -$39.9M
$123M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sight Sciences has a last 12-month revenue (LTM) of $76.8M and a last 12-month EBITDA of -$39.9M.
In the most recent fiscal year, Sight Sciences achieved revenue of $79.9M and an EBITDA of -$45.9M.
Sight Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sight Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $76.8M | XXX | $79.9M | XXX | XXX | XXX |
| Gross Profit | $64.5M | XXX | $68.3M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | -$39.9M | XXX | -$45.9M | XXX | XXX | XXX |
| EBITDA Margin | -52% | XXX | -57% | XXX | XXX | XXX |
| EBIT | -$49.0M | XXX | -$50.5M | XXX | XXX | XXX |
| EBIT Margin | -64% | XXX | -63% | XXX | XXX | XXX |
| Net Profit | -$53.1M | XXX | -$51.5M | XXX | XXX | XXX |
| Net Margin | -69% | XXX | -64% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sight Sciences's stock price is $4.
Sight Sciences has current market cap of $191M, and EV of $123M.
See Sight Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $123M | $191M | XXX | XXX | XXX | XXX | $-1.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sight Sciences has market cap of $191M and EV of $123M.
Sight Sciences's trades at 1.5x EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Sight Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sight Sciences has a P/E ratio of -3.6x.
See valuation multiples for Sight Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $191M | XXX | $191M | XXX | XXX | XXX |
| EV (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | -3.1x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.6x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSight Sciences's last 12 month revenue growth is -1%
Sight Sciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.
Sight Sciences's rule of 40 is -62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sight Sciences's rule of X is -55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sight Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | -52% | XXX | -57% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -62% | XXX | -59% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 149% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sight Sciences acquired XXX companies to date.
Last acquisition by Sight Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Sight Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sight Sciences founded? | Sight Sciences was founded in 2010. |
| Where is Sight Sciences headquartered? | Sight Sciences is headquartered in United States of America. |
| How many employees does Sight Sciences have? | As of today, Sight Sciences has 216 employees. |
| Who is the CEO of Sight Sciences? | Sight Sciences's CEO is Mr. Paul Badawi. |
| Is Sight Sciences publicy listed? | Yes, Sight Sciences is a public company listed on NAS. |
| What is the stock symbol of Sight Sciences? | Sight Sciences trades under SGHT ticker. |
| When did Sight Sciences go public? | Sight Sciences went public in 2021. |
| Who are competitors of Sight Sciences? | Similar companies to Sight Sciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sight Sciences? | Sight Sciences's current market cap is $191M |
| What is the current revenue of Sight Sciences? | Sight Sciences's last 12 months revenue is $76.8M. |
| What is the current revenue growth of Sight Sciences? | Sight Sciences revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Sight Sciences? | Current revenue multiple of Sight Sciences is 1.6x. |
| Is Sight Sciences profitable? | Yes, Sight Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sight Sciences? | Sight Sciences's last 12 months EBITDA is -$39.9M. |
| What is Sight Sciences's EBITDA margin? | Sight Sciences's last 12 months EBITDA margin is -52%. |
| What is the current EV/EBITDA multiple of Sight Sciences? | Current EBITDA multiple of Sight Sciences is -3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
